VA
TXG icon

Vident Advisory’s 10x Genomics TXG Stock Holding History

Vident Advisory’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Buy
+9,273
New +$243K ﹤0.01% 1536
2025
Q3 		– Sell
-13,998
Closed -$162K – 1738
2025
Q2 		$162K Buy
+13,998
New +$128K ﹤0.01% 1527
2024
Q3 		– Sell
-11,999
Closed -$233K – 1553
2024
Q2 		$233K Buy
11,999
+4,171
+53% +$109K 0.01% 1218
2024
Q1 		$294K Buy
7,828
+798
+11% +$35.1K 0.01% 1033
2023
Q4 		$393K Sell
7,030
-117
-2% -$5.09K 0.01% 890
2023
Q3 		$295K Buy
+7,147
New +$372K 0.01% 918

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vident Advisory's TXG Position: Q2 2026 in Review

Vident Advisory opened a new position in 10x Genomics (TXG) in Q2 2026: 9,273 shares worth $356K. The stake represents ﹤0.01% of the portfolio and ranks #1536 among its holdings. This is a return to the name: Vident Advisory previously reported a position in TXG as recently as Q2 2025.

Vident Advisory first reported a position in TXG in Q3 2023 and has held it in 6 quarters since. The position peaked at $393K in Q4 2023. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Vident Advisory held 9,273 shares of 10x Genomics worth $356K as of Q2 2026.
  • 10x Genomics was a new Vident Advisory position in Q2 2026.
  • 10x Genomics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1536 holding.
  • Vident Advisory first reported a position in 10x Genomics in Q3 2023 and has held it in 6 quarters since.
  • Vident Advisory's 10x Genomics position peaked at $393K in Q4 2023.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.